117 related articles for article (PubMed ID: 22856387)
1. Pharmacokinetic characterization of the novel TAZ modulator TM-25659 using a multicompartment kinetic model in rats and a possibility of its drug-drug interactions in humans.
Lee KR; Choi SH; Song JS; Kwak EY; Chae YJ; Im SH; Lee BH; Seo H; Cho WK; Kim MS; Kim NJ; Ahn SH; Bae MA
Xenobiotica; 2013 Feb; 43(2):193-200. PubMed ID: 22856387
[TBL] [Abstract][Full Text] [Related]
2. Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.
Choi MK; Kwon M; Ahn JH; Kim NJ; Bae MA; Song IS
Biopharm Drug Dispos; 2014 Apr; 35(3):183-94. PubMed ID: 24285344
[TBL] [Abstract][Full Text] [Related]
3. Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry.
Choi SH; Lee KR; Woo JC; Kim NJ; Moon DC; Hwang ES; Ahn SH; Bae MA; Kim MS
J Pharm Biomed Anal; 2012 Apr; 63():47-52. PubMed ID: 22357285
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
6. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
7. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
Lee KR; Jeong JW; Hyun HC; Jang E; Ahn S; Choi S; Joo SH; Kim S; Koo TS
Xenobiotica; 2018 Aug; 48(8):831-838. PubMed ID: 28803538
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Kim TH; Jeong JW; Song JH; Lee KR; Ahn S; Ahn SH; Kim S; Koo TS
Arch Pharm Res; 2015 Nov; 38(11):2076-82. PubMed ID: 25956695
[TBL] [Abstract][Full Text] [Related]
15. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.
Bymaster FP; Chao P; Schulze H; Tran PV; Marshall RD
Drug Metab Lett; 2013 Mar; 7(1):23-33. PubMed ID: 23826879
[TBL] [Abstract][Full Text] [Related]
18. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Lee KR; Chae YJ; Koo TS
Xenobiotica; 2011 Dec; 41(12):1100-7. PubMed ID: 21838595
[TBL] [Abstract][Full Text] [Related]
20. Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.
Dockens RC; Santone KS; Mitroka JG; Morrison RA; Jemal M; Greene DS; Barbhaiya RH
Drug Metab Dispos; 2000 Aug; 28(8):973-80. PubMed ID: 10901709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
